In non-small cell lung cancer and renal cell carcinoma, two PD-L1 inhibitors (durvalumab and atezolizumab) have demonstrated a manageable safety profile and great antitumour activity, including the prolongation of prognosis-free survival and inhibition of metastases [39,40]. This evidence concerns the gene CD274 and renal cell carcinoma.